Compare Novartis AG (NVS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs DENTSPLY SIRONA Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while DENTSPLY SIRONA Inc trades at $13.56 (market cap $2.70B). The key difference: Novartis AG is far larger — about 107.5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| NVS | XRAY | |
|---|---|---|
Market Cap | $290.25B | $2.70B |
Sector | Health | Health |
52-Week High | $168.62 | $16.85 |
52-Week Low | $113.50 | $9.64 |
Enterprise Value | $330.27B | $4.84B |
Dividend Yield | 3.17% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Dentsply Sirona (XRAY) trades at $13.65, down 2.91% on the day, with a mixed technical picture showing a bullish moving average signal but overbought RSI levels. Fundamentally, the company reported a net loss of $598 million for 2025, with negative profit margins and an elevated EV/EBITDA of 91.48, though revenue remains stable near $3.7 billion. Recent news includes the appointment of a new CFO and expanded U.S. distribution partnerships, while the upcoming Q2 2026 earnings call on August 6 is a key near-term catalyst.
The outlook remains challenging due to persistent losses and margin pressure, offset by strategic growth initiatives. Investment opportunities lie in the company's market leadership and digital dentistry expansion, but risks include high debt levels, competitive pressures, and the need for a successful turnaround. Analyst consensus is Hold with a price target of $13.33, indicating limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
